Nanobiotix S.A. (EPA: NANO)
4.984
+0.104 (2.13%)
Aug 30, 2024, 5:35 PM CET
Nanobiotix Employees
Nanobiotix had 102 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
102
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
€354,980
Profits / Employee
€389,216
Market Cap
236.27M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
LVMH Moët Hennessy - Louis Vuitton, Société Européenne | 192,287 |
Hermès International Société en commandite par actions | 22,037 |
L'Oréal S.A. | 94,605 |
Schneider Electric S.E. | 168,000 |
Christian Dior SE | 196,686 |
EssilorLuxottica Société anonyme | 151,292 |
L'Air Liquide S.A. | 67,778 |
Nanobiotix News
- 2 months ago - NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024 - GlobeNewsWire
- 3 months ago - Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy - GlobeNewsWire
- 3 months ago - NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call - GlobeNewsWire
- 3 months ago - NANOBIOTIX to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 3 months ago - NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update - GlobeNewsWire
- 3 months ago - Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth - GlobeNewsWire
- 3 months ago - NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024 - GlobeNewsWire
- 3 months ago - NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer - GlobeNewsWire